Company Overview
Snapshot
Founded in August 2019 by Prof. Marcel Machluf, NanoGhost operates with 11–50 employees. The company has raised $9 million across two funding rounds from two investors.
Business overview
NanoGhost is a Health Tech & Life Sciences company developing a drug-delivery technology that utilizes adult stem cells to precisely transport medicine to tumor sites. Its core technology is based on Nano-Ghosts (NGs), nano-vesicles reconstructed from the cell membranes of naturally targeted allogeneic mesenchymal stem cells (MSCs). This platform retains the MSCs' inherent targeting capabilities for inflamed and malignant tissues, enabling reduced drug dosages and enhanced efficacy. The company primarily serves the pharmaceutical industry, focusing on cancer treatments in markets including Europe, India, China, and the United States.
Strategic signal
In November 2021, NanoGhost's technology was highlighted for its potential to reduce cancer drug dosages a millionfold. This signals a significant advancement in targeted cancer therapy, indicating the company's platform could dramatically improve treatment efficacy and patient outcomes while minimizing side effects, positioning NanoGhost as a key innovator in precision medicine.
Log in to access full profile ›Company Intelligence Q&A
- What is NanoGhost's core technology?
- NanoGhost's core technology involves Nano-Ghosts (NGs), which are nano-vesicles reconstructed from the cell membranes of naturally targeted allogeneic mesenchymal stem cells (MSCs). These NGs deliver medicine directly to tumor sites, retaining the MSCs' targeting capabilities.
- When was NanoGhost founded and by whom?
- NanoGhost was founded in August 2019 by Prof. Marcel Machluf, who is also the inventor of the technology.
- What recognition has NanoGhost received for its technology?
- Israel's Ministry of Science and Technology named NanoGhost as one of Israel's 60 most impactful developments, recognizing its innovative drug delivery platform.